Novartis AG

LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY (2021) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen P, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL (2021) Boers M, Conaghan PG, Schett G, Mandl P, Naredo E, Van Den Bosch F, Burgos-Vargas R, et al. Conference contribution TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY (2021) D'Agostino MA, Conaghan PG, Gaillez C, Boers M, Naredo E, Carron P, Hanova P, et al. Conference contribution ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED (2021) Kaeley GS, Schett G, Conaghan PG, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ROTATOR CUFF TENDINOPATHY: A 24-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II PROOF-OF-CONCEPT TRIAL (2021) Millar NL, Mcinnes I, Mindeholm L, Seroutou A, Praestgaard J, Schramm U, Levitch R, et al. Conference contribution Despite large choice of effective therapies: Individuals with psoriasis still seem undertreated (2021) Pilz AC, Zink A, Schielein MC, Hell K, Romer K, Hillmann E, Baumer D, et al. Journal article Patients with Chronic Urticaria Remain Largely Undertreated: Results from the DERMLINE Online Survey (2021) Wagner N, Zink A, Hell K, Reinhardt M, Romer K, Hillmann E, Baeumer D, Schielein MC Journal article Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2,-3, and-7 trials: Additional results and key subgroup findings (2021) Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir NS, Conejo EA, et al. Conference contribution Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms (2021) Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, et al. Journal article Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution